These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7908879)

  • 41. Piroxicam immediate release formulations: A fasting randomized open-label crossover bioequivalence study in healthy volunteers.
    Helmy SA; El-Bedaiwy HM
    Clin Pharmacol Drug Dev; 2014 Nov; 3(6):466-71. PubMed ID: 27129120
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mefloquine pharmacokinetics in healthy subjects and in peptic ulcer patients after cimetidine administration.
    Kolawole JA; Mustapha A; Abudu-Aguye I; Ochekpe N
    Eur J Drug Metab Pharmacokinet; 2000; 25(3-4):165-70. PubMed ID: 11420885
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quantification of piroxicam and 5'-hydroxypiroxicam in human plasma and saliva using liquid chromatography-tandem mass spectrometry following oral administration.
    Calvo AM; Santos GM; Dionísio TJ; Marques MP; Brozoski DT; Lanchote VL; Fernandes MH; Faria FA; Santos CF
    J Pharm Biomed Anal; 2016 Feb; 120():212-20. PubMed ID: 26760238
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: contribution of type I system.
    Nakamura H; Sano H; Yamazaki M; Sugiyama Y
    J Pharmacol Exp Ther; 1994 Jun; 269(3):1220-7. PubMed ID: 7912279
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical studies on the use of roxatidine acetate for the treatment of peptic ulcer in Japan.
    Inoue M
    Drugs; 1988; 35 Suppl 3():114-9. PubMed ID: 2905239
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [What is important in treating elderly with H2 receptor antagonists].
    Kurosawa S
    Nihon Rinsho; 2002 Aug; 60(8):1613-7. PubMed ID: 12187760
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatic effects of drugs used in the treatment of peptic ulcer disease.
    Lewis JH
    Am J Gastroenterol; 1987 Oct; 82(10):987-1003. PubMed ID: 2889354
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects.
    Sitsen JM; Maris FA; Timmer CJ
    Eur J Clin Pharmacol; 2000 Aug; 56(5):389-94. PubMed ID: 11009047
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The status of H2-blocker therapy today].
    Rameis H
    Wien Med Wochenschr; 1992; 142(18):398-405. PubMed ID: 1362029
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.
    Slichenmyer WJ; Donehower RC; Chen TL; Bowling MK; McGuire WP; Rowinsky EK
    Cancer Chemother Pharmacol; 1995; 36(3):227-32. PubMed ID: 7781143
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin.
    Hammond JB; Offen WW
    Am J Gastroenterol; 1988 Jan; 83(1):32-6. PubMed ID: 2892392
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Two-Period Open-Label, Single-Dose Crossover Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Between Cimetidine and Inhaled Extrafine CHF 5993.
    Mariotti F; Ciurlia G; Spaccapelo L; Muraro A; Acerbi D
    Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):269-279. PubMed ID: 27209586
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of H2-receptor antagonist and proton pump inhibitor on microbial proliferation in the stomach.
    Wang K; Lin HJ; Perng CL; Tseng GY; Yu KW; Chang FY; Lee SD
    Hepatogastroenterology; 2004; 51(59):1540-3. PubMed ID: 15362796
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Giant gastric ulcer: its natural history and outcome in the H2RA era.
    Raju GS; Bardhan KD; Royston C; Beresford J
    Am J Gastroenterol; 1999 Dec; 94(12):3478-86. PubMed ID: 10606307
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical pharmacokinetics of lornoxicam. A short half-life oxicam.
    Skjodt NM; Davies NM
    Clin Pharmacokinet; 1998 Jun; 34(6):421-8. PubMed ID: 9646006
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug interactions avoided-a useful indicator of good prescribing practice.
    Williams D; Kelly A; Feely J
    Br J Clin Pharmacol; 2000 Apr; 49(4):369-72. PubMed ID: 10759693
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Control of gastric acid with high dose H2-receptor antagonists after omeprazole failure: report of two cases.
    Leite LP; Just RJ; Castell DO; Lagerström PO
    Am J Gastroenterol; 1995 Oct; 90(10):1874-7. PubMed ID: 7572913
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nizatidine in peptic ulcer disease. Proceeedings of the First International Symposium on Nizatidine. Vienna, 11 and 12 October 1986.
    Scand J Gastroenterol Suppl; 1987; 136():1-88. PubMed ID: 2892250
    [No Abstract]   [Full Text] [Related]  

  • 60. Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine.
    Assunção SS; Ruschel SI; Rosa Lde C; Campos JA; Alves MJ; Bracco OL; de Lima MS
    Braz J Psychiatry; 2006 Dec; 28(4):270-6. PubMed ID: 17242805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.